Healthcare provider profile · identity verified

John Rinker, DO

Family Practice · PONTIAC, IL · NPI 1255449393

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	384	88
Levothyroxine Sodium	Levothyroxine Sodium	339	81
Amlodipine Besylate	Amlodipine Besylate	312	62
Metoprolol Succinate	Metoprolol Succinate	223	47
Lisinopril	Lisinopril	198	54
Metformin Hcl	Metformin Hcl	195	47
Losartan Potassium	Losartan Potassium	186	49
Gabapentin	Gabapentin	171	42
Omeprazole	Omeprazole	168	48
Simvastatin	Simvastatin	142	37
Tramadol Hcl	Tramadol Hcl	133	19
Alprazolam	Alprazolam	132	23
Tamsulosin Hcl	Tamsulosin Hcl	117	29
Jardiance	Empagliflozin	108	19
Rosuvastatin Calcium	Rosuvastatin Calcium	108	39
Prednisone	Prednisone	106	43
Pravastatin Sodium	Pravastatin Sodium	97	22
Furosemide	Furosemide	96	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	93	20
Enalapril Maleate	Enalapril Maleate	92	24
Duloxetine Hcl	Duloxetine Hcl	88	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	85	18
Escitalopram Oxalate	Escitalopram Oxalate	81	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	80	24
Pantoprazole Sodium	Pantoprazole Sodium	79	19
Metoprolol Tartrate	Metoprolol Tartrate	76	22
Montelukast Sodium	Montelukast Sodium	70	17
Atenolol	Atenolol	65	14
Venlafaxine Hcl Er	Venlafaxine Hcl	62	suppressed
Potassium Chloride	Potassium Chloride	60	15
Sertraline Hcl	Sertraline Hcl	60	19
Warfarin Sodium	Warfarin Sodium	60	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	56	16
Donepezil Hcl	Donepezil Hcl	55	suppressed
Xarelto	Rivaroxaban	55	suppressed
Eliquis	Apixaban	54	18
Albuterol Sulfate Hfa	Albuterol Sulfate	50	17
Ozempic	Semaglutide	49	suppressed
Clonazepam	Clonazepam	45	suppressed
Clopidogrel	Clopidogrel Bisulfate	41	13
Trazodone Hcl	Trazodone Hcl	41	11
Azithromycin	Azithromycin	40	34
Levetiracetam	Levetiracetam	40	suppressed
Spironolactone	Spironolactone	40	15
Topiramate	Topiramate	40	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	39	suppressed
Carvedilol	Carvedilol	37	11
Mirtazapine	Mirtazapine	37	suppressed
Cephalexin	Cephalexin	36	26
Farxiga	Dapagliflozin Propanediol	36	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	34	suppressed
Meloxicam	Meloxicam	34	12
Alendronate Sodium	Alendronate Sodium	33	suppressed
Ondansetron Hcl	Ondansetron Hcl	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	32	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	32	suppressed
Nifedipine Er	Nifedipine	32	suppressed
Fenofibrate	Fenofibrate	31	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	30	23
Famotidine	Famotidine	30	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	11
Lovastatin	Lovastatin	29	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	29	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	29	suppressed
Pregabalin	Pregabalin	29	suppressed
Allopurinol	Allopurinol	28	suppressed
Midodrine Hcl	Midodrine Hcl	28	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Hydralazine Hcl	Hydralazine Hcl	27	suppressed
Temazepam	Temazepam	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	17
Divalproex Sodium	Divalproex Sodium	26	suppressed
Finasteride	Finasteride	26	suppressed
Memantine Hcl	Memantine Hcl	26	suppressed
Humalog Kwikpen U-100	Insulin Lispro	24	suppressed
Baclofen	Baclofen	23	suppressed
Cilostazol	Cilostazol	23	suppressed
Glipizide	Glipizide	23	suppressed
Methylprednisolone	Methylprednisolone	23	20
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	22	19
Klor-Con M20	Potassium Chloride	21	suppressed
Metformin Hcl Er	Metformin Hcl	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	21	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	18	suppressed
Spiriva Handihaler	Tiotropium Bromide	18	suppressed
Estradiol	Estradiol	17	11
Lidocaine	Lidocaine	17	suppressed
Torsemide	Torsemide	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Estradiol (Once Weekly)	Estradiol	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Verapamil Hcl	Verapamil Hcl	13	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Progesterone	Progesterone, Micronized	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error